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Abstract
Background: The enhancement of cell motility is a critical event during tumor cell spreading. Since myosin light chain
kinase (MLCK) regulates cell behavior, it is regarded as a promising target in terms of preventing tumor invasion and
metastasis. Since MLCK was identified to be associated with human arrest defective-1 (hARD1) through yeast two-hybrid
screening, we here tested the possibility that hARD1 acts as a regulator of MLCK and by so doing controls tumor cell
motility.
Methodology/Principal Findings: The physical interaction between MLCK and hARD1 was confirmed both in vivo and in
vitro by immunoprecipitation assay and affinity chromatography. hARD1, which is known to have the activity of protein
lysine e-acetylation, bound to and acetylated MLCK activated by Ca
2+ signaling, and by so doing deactivated MLCK, which
led to a reduction in the phosphorylation of MLC. Furthermore, hARD1 inhibited tumor cell migration and invasion MLCK-
dependently. Our mutation study revealed that hARD1 associated with an IgG motif of MLCK and acetylated the Lys608
residue in this motif. The K608A-mutated MLCK was neither acetylated nor inactivated by hARD1, and its stimulatory effect
on cell motility was not inhibited by hARD1.
Conclusion/Significance: These results indicate that hARD1 is a bona fide regulator of MLCK, and that hARD1 plays a crucial
role in the balance between tumor cell migration and stasis. Thus, hARD1 could be a therapeutic target in the context of
preventing tumor invasion and metastasis.
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Introduction
Despite substantial improvements in cancer therapy, tumor
invasion and metastasis remain the main causes of cancer death.
Tumor invasion and metastasis are complicated processes, which
involve alterations to cell adhesion, the proteolysis of matrix
proteins, increased cell motility, intra/extravasation, and coloni-
zation at distant sites [1]. Since tumor cell migration is a key step
in tumor spread, to identify key regulators of cell motility might
provide novel therapeutic possibilities. In this respect, myosin light
chain kinase (MLCK) is regarded as a target for preventing tumor
spread. Indeed, MLCK activation and expression have been found
to be positively related with metastatic propensity [2,3]. Moreover,
MLCK inhibitors have been shown to diminish the invasiveness of
various cancer cells [4,5]. Therefore, it is worth while to
understand the regulatory mechanism of MLCK in order to
search for novel targets for preventing tumor spread.
MLCK is a Ca
2+/calmodulin-dependent protein kinase that
regulates a variety of cellular functions, such as, muscle
contraction and cell migration. In mammals, MLCK proteins
are encoded by two genes, namely, mylk1 and mylk2 [6,7]. The
mylk1 gene is ubiquitously expressed in smooth muscle and non-
muscle cells, whereas the mylk2 is exclusively expressed in skeletal
muscle cells [8–10]. The mylk1 gene expresses at least four
transcripts derived from independent promoters, namely, two long
MLCKs, short MLCK, and telokin. Short MLCK (,130 kDa) is
expressed mainly in smooth muscle cells and long MLCK (,210
kDa) is expressed in non-muscle cells [11]. Furthermore, long
MLCK is expressed in several variant forms due to alternative
mRNA splicing. Structurally, short MLCK has three immuno-
globulin (Ig) motifs, one fibronectin-like (Fn) motif, a PEVK-rich
repeat region, and three DFRXXL repeats in its N-terminus. Long
MLCK is identical to short MLCK but has six additional Ig motifs
and two additional DXRXXL motifs in its N-terminal extension
region [12,13].
From a mechanistic point of view, when cytosolic Ca
2+
concentrations increase, Ca
2+/calmodulin complex activates
MLCK, which in turn phosphorylates the Thr18 and Ser19
residues in myosin light chain (MLC) [11,14]. In addition, MLCK
activity is finely regulated by the protein kinase network. Activated
MLC is dephosphorylated and deactivated by protein phosphatase
(PP)-IM [15,16]. Furthermore, in addition to MLCK, Rho-kinase
can phosphorylate MLC independently of Ca
2+ and calmodulin
[17]. Rho-kinase also phosphorylates PP-1M, which in turn
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[18]. Finally, MLC phosphorylation stimulates myofilament
assembly and myosin ATPase activity [19]. As a consequence,
MLC phosphorylation enhances many contractile processes, such
as, muscle contraction, stress fiber formation, focal adhesion, cell
migration, and cytokinesis [6,11].
Arrest defective-1 (ARD1) was first identified in Saccharomyces
cerevisiae [20], and was subsequently found to act as an
acetyltransferase and to regulate cell entry into the stationary
phase and sporulation in yeast [21,22]. Like yeast ARD1,
mammalian homologues of ARD1 acetylate the N-terminal a-
amino group of some proteins in association with N-acetyltrans-
ferase [23,24]. In addition, mammalian ARD1s can acetylate the
e-amino group of lysine, for example, mouse ARD1 has been
reported to acetylate Lys532 of HIF-1a and to promote HIF-1a
ubiquitination and degradation [25,26]. More recently, human
ARD1 was reported to enhance lung cancer cell proliferation by
acetylating and activating b-catenin [27]. Therefore, it is believed
that ARD1 has diverse biological functions in mammalian cells,
and that it acetylates various molecules in addition to HIF-1a and
b-catenin.
In the present study, yeast two-hybrid assays showed that
human ARD1 (hARD1) binds with long MLCK. Based on this
interaction, we hypothesized that hARD1 acetylates long MLCK
and that acetylated long MLCK affects tumor cell behaviors like
migration and invasion. It was found that hARD1 binds to the N-
terminal motif of long MLCK and acetylates a lysine residue
within this motif. Furthermore, this hARD1-mediated acetylation
was found to inactivate long MLCK, and thereby, to inhibit MLC
phosphorylation, which in turn inhibited tumor cell migration and
invasion. Based on these results, we propose that hARD1, an
endogenous inhibitor of MLCK, plays a critical role in the control
of tumor cell behavior, and suggest that hARD1 be viewed as a
novel target molecule for the prevention of tumor invasion and
metastasis.
Results
hARD1 associates with MLCK
We screened a human liver cDNA library using the yeast two-
hybrid method using full-length hARD1 as bait. Of twelve positive
clones, three clones contained cDNA encoding aa. 357–578 of long
MLCK transcript variant 2. We co-transfected HEK293 cells with
GFP-ARD1 and HA-MLCK (357–578) plasmids and found that
these peptides were co-precipitated (Fig. 1A). Since long MLCK
variant 1 has 75 amino acids in addition to the entire sequence of
variant 2, it was also expected to associate with hARD1. Both types
of MLCK were co-precipitated with hARD1 (Figures 1B and 1C).
These interactions were also crosschecked by changing the
antibodies used for immunoprecipitation and immunoblotting. To
identify the association between endogenous hARD1 and long
MLCK, we chose HT1080 cell line which had been identified to
express both hARD1 and long MLCK at high levels in a
preliminary study. As expected, hARD1 and MLCK were shown
to be naturally associated in HT1080 cells (Fig. 1D). Because long
MLCK variant 1 is known to be more widely distributed than
variant 2, we decided to study only long MLCK variant 1 in the
following experiments and hereafter refer to it as MLCK.
hARD1 binds and acetylates MLCK activated by Ca
2+/
calmodulin
MLCK is phosphorylated and activated by Ca
2+ signaling
[6,11]. To examine whether the MLCK/hARD1 interaction
depends on MLCK activation, HT1080 cells were treated with
ionomycin and PMA, which are known to activate MLCK by
inducing Ca
2+ influx and MLCK phophorylation, alternatively,
cells were treated with BAPTA-AM to remove intracellular Ca
2+.
It is shown in Figure S1 that these reagents at the concentrations
used did not affect cell viability. The hARD1/MLCK interaction
was robustly stimulated by Ca
2+ influx, which was abolished by
Ca
2+ chelation (Fig. 2A). This suggests that hARD1 primarily
interacts with Ca
2+-activated MLCK rather than inactive MLCK.
Also, the MLCK was phosphorylated at Ser439 Ca
2+-dependently
and the phosphorylated MLCK was co-precipitated with hARD1
(Fig. 2A). Therefore, it is also possible that the MLCK/hARD1
interaction is affected by the MLCK phosphorylatin. We next
tested the possibility that hARD1 acetylates the lysine residues of
MLCK. The lysyl-acetylation of MLCK was stimulated by
ionomycin/PMA and inhibited by BAPTA-AM, which was also
associated with the phosphorylation of MLCK (Fig. 2B). In
addition, the acetylated MLCK levels increased in the presence of
TSA (a deacetylase inhibitor), which indicates that this acetylation
can be reversed by some deacetylase. The Ca
2+-mediated MLCK
acetylation was further increased by hARD1 expression and
abolished by hARD1 knock-down (Fig. 2C). To examine whether
hARD1 naturally acetylates MLCK, we suppressed the expression
of endogenous hARD1 using three siRNAs targeting different
sequences of hARD mRNA. These siRNAs down-regulated
hARD1, and also noticeably reduced the cellular levels of
acetylated MLCK. Taken together, hARD1 may function to
lysyl-acetylate endogenous and expressed MLCK.
hARD1 inhibits the phosphorylation of MLC by
inactivating MLCK
To understand the consequences of MLCK acetylation, we
analyzed the phosphorylation of MLC in HT1080 cells transfected
with hARD1 plasmid or siRNA. Phospho-MLC levels were found
to be noticeably reduced by hARD1 overexpression, and increased
by hARD1 knock-down (Fig. 3A). These results suggest that
MLCK is functionally inhibited by hARD1. Furthermore, because
MLC can be phosphorylated by either MLCK or Rho-kinase, we
sought to indentify the kinase linked with hARD1-dependent
MLC dephosphorylation. In HT1080 cells treated with DMSO-
vehicle only, phospho-MLC levels were found to be inversely
correlated with hARD1 expression (Figs. 3B and 3C, the DMSO
group). MLCK inhibitors ML7 and ML9 reduced phospho-MLC
levels in all groups tested and more importantly, the effects of
hARD1 on MLC phosphorylation were abolished by MLCK
inhibition (Fig. 3B). When cells were treated with a Rho-kinase
inhibitor Y27632, MLC phosphorylation was also partially
reduced, but this phosphorylation was still regulated hARD1-
dependently (Fig. 3C). These inhibitors used were confirmed not
to affect cell viability (Figure S1). These findings indicate that
although MLC phosphorylation is mediated by both MLCK and
Rho-kinase in HT1080 cells, only MLCK-mediated MLC
phosphorylation is likely to be regulated by hARD1.
hARD1 inhibits cell migration and invasion
Since the MLCK-MLC pathway is known to regulate cell
contraction and migration, we investigated if hARD1 controls
tumor cell migration and invasion by inhibiting this pathway.
hARD1 overexpression was found to reduce the number of
migrating cells by 52%, but hARD1 knock-down enhanced cell
migration by 94%, and this enhancement was attenuated by
hARD1 overexpression (Fig. 4A). Invasion assays also demon-
strated that cell invasion was negatively regulated by hARD1
(Fig. 4B). These results suggest that hARD1 appears to function as
a negative regulator of tumor cell migration and invasion.
MLCK Regulation by ARD1
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To examine whether hARD1 inhibits cell motility via MLCK,
transfected HT1080 cells were treated with ML7 or ML9. The
MLCK inhibitors significantly inhibited the cell migration and
invasion, and also abolished the stimulatory effect of hARD1
knock-down on the cell motility. However, the MLCK inhibitors
did not further inhibit the cell migration and invasion below the
levels in hARD1-overexpressing cells (Fig. 4C and Fig. 4D). These
results suggest that the action of hARD1 is due to its inactivation
of MLCK. Furthermore, because stress fiber and actin filament
formations are regulated by MLCK, we examined how cytoskel-
etal organization is regulated by hARD1. Filamentous actin (F-
actin) of HT1080 cells treated with ML7 or ML9 was thinner than
in untreated control cells, and a similar finding was observed in
hARD1 overexpressing cells. Conversely, F-actin was thicker in
hARD1 knocked-down cells, but became thinner by treatment of
MLCK inhibitors (Figure S2). These results support the notion
that hARD1 inhibits tumor cell migration and invasion by
inhibiting MLCK. However, since both ML-7 and ML-9 could
target molecules other than MLCK, it should be noted that the
MLCK dependent action of hARD1 remains to be further
investigated.
Identification of the hARD1-binding domain of MLCK
To identify the region of MLCK targeted by hARD1, we co-
transfected HEK293 cells with hARD1 plasmid and each of the
five Myc-tagged plasmids expressing different MLCK segments.
hARD1 was precipitated with anti-ARD1 antibody and was found
to associate with MLCK_B of the N-terminal extension region
(Fig. 5A). Furthermore, MLCK_B was found to be specifically
acetylated by hARD1 in cells (Fig. 5B). Moreover, when TSA was
omitted from culture medium, acetylated MLCK_B levels were
significantly reduced. To examine the interaction between hARD1
and MLCK_B further, we mixed in vitro His-ARD1 with each of
the five Myc-MLCK fragments. The purity (.97%) of His-
hARD1 used was assessed by protein staining (Figure S3). After
protein mixtures were pulled-down with Ni-NTA beads, immu-
noblotting was conducted with anti-Myc antibody. Of the five
fragments, only MLCK_B was found to directly bind His-ARD1
(Fig. 5C). Next, we performed an in vitro acetylation assay, and of
Figure 1. hARD1 associates with long MLCKs. (A–C) Interaction between expressed hARD1 and expressed long MLCKs. HT1080 cells were co-
transfected with plasmids (4 mg each per 100 W dish) of GFP-ARD1 and MLCK variant 2 fragment (aa. 357–578) (A), ARD1 and full-length long MLCK
variant 2 (MLCKv2) (B), or ARD1 and full-length long MLCK variant 1 (MLCKv1) (C). GFP-ARD1 or ARD1 was immunoprecipitated with anti-GFP, anti-
ARD1, or non-immunized rat serum (IgG), and co-precipitated MLCKs were analyzed using anti-HA or anti-MLCK antibody. Otherwise, HA-MLCK or
MLCK was immunoprecipitated with anti-HA, anti-MLCK, or non-immunized mouse serum (IgG), and co-precipitated ARD1 was identified using anti-
GFP or anti-ARD1 antibody. (D) Interaction between endogenous hARD1 and long MLCK. In HT1080 cells, ARD1 was immunoprecipitated with anti-
ARD1 or non-immunized serum, and co-precipitated MLCK was identified using anti-MLCK antibody (left panel). The interaction was also cross-
checked by changing antibodies (right panel).
doi:10.1371/journal.pone.0007451.g001
MLCK Regulation by ARD1
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2+ signaling. (A) The hARD1-MLCK interaction is stimulated
by the Ca
2+ signaling. HT1080 cells were co-transfected with 4 mg each of pcARD1 and pcMLCK. The cells were treated with 1 mM ionomycin (IM) and
30 nM phorbol myristate acetate (PMA) for 8 h, or 20 mM BAPTA-AM for 3 h. MLCK was co-immunoprecipitated by anti-ARD1 antibody. Co-
precipitated proteins were analyzed by immunoblotting (upper panel). The input levels were analyzed by immunoblotting (lower panel). (B) The
lysyl-acetylation of MLCK is augmented by Ca
2+ signaling. Untransfected HT1080 cells were treated with ionomycin and PMA for 8 h or BAPTA-AM for
3 h, alternatively, Trichostatin-A (TSA) at 500 nM was treated for 5 h before cell harvest. The cell lysates were immunoprecipitated with anti-MLCK
antibody, and immunoblotted by anti-acetyl-lysine or anti-MLCK antibody. (C) MLCK is acetylated by hARD1. HT1080 cells were transfected with
pcARD1 (4 mg) or ARD1-silencing RNA (si-ARD1, 80 nM), and then treated with ionomycin and PMA for 8 h. In the samples immunoprecipitated with
anti-MLCK antibody, total MLCK and acetylated MLCK were analyzed by immunoblotting. (D) Endogenous MLCK is acetylated hARD1-dependently.
Endogenous MLCK was down-regulated in HT1080 cells using each of three siRNAs (80 nM) targeting different sites of ARD1 mRNA, and then treated
with ionomycin and PMA for 8 h. Acetylated MLCK was immunoprecipitated by anti-MLCK antibody and immunoblotted with anti-acetyl-lysine
antibody. Input protein levels were analyzed by immuboblotting with specific antibodies.
doi:10.1371/journal.pone.0007451.g002
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(Fig. 5D). These results suggest that hARD1 targets and acetylates
a lysine within the aa.272–666 of MLCK.
Lys608 acetylation of MLCK is responsible for hARD1
control of cell behavior
To identify the lysine residue acetylated by hARD1, we
constructed a Flag/SBP-tagged recombinant protein (aa.497–
666), which did not contain the overlap region in MLCK_A and B
and the 75 amino acid region missing in MLCK variant 2. Purified
His-ARD1 and Flag/SBP-(497–666) were mixed with acetyl-CoA
in the acetylation reaction buffer. The purities of both peptides
were .97% (Figure S3). We also confirmed that Flag/SBP-(497–
666) was acetylated by His-ARD1 in vitro (Fig. 6A, the 1
st column).
MLCK has six lysine residues in its aa. 497 to 666 region, namely,
K512, K603, K604, K608, K619, and K633. To identify the
lysine residue acetylated by hARD1, we substituted each of these
six lysines with arginine to produce five mutants. As shown in
Fig. 6A, Flag-SBP-K608R peptide alone was not acetylated by
His-ARD1. To determine whether Lys608 was the main site
acetylated by hARD1, we constructed the full-length K608R
mutant and transfected it into HT1080 cells. As previously
demonstrated, the acetylation of wild-type MLCK was found to be
markedly increased by hARD1 expression. However, K608R
mutant was not further acetylated by hARD1 (Fig. 6B), indicating
that hARD1 specifically acetylated the Lys608 residue in an IgG
domain of MLCK. We next examined whether Lys608 of MLCK
is required for hARD1 to inhibit MLC activity and tumor cell
behavior. The full-length K608R stimulated the phosphorylation
of MLC in the same manner as wild-type MLCK. However, this
effect of K608R was not significantly affected by hARD1
expression (Fig. 6C). Likewise, the effects of K608R on cell
migration and invasion were not significantly attenuated by
hARD1 expression (Fig. 6D). These findings indicate that the
hARD1-mediated Lys608 acetylation of MLCK is an important
regulator of tumor cell behavior.
Discussion
Initially, it was found that hARD1 and long MLCK interacted
in the yeast two-hybrid system. This interaction was later
confirmed in human cancer cells. hARD1 bound to and acetylated
MLCK activated by Ca
2+ signaling, and by so doing deactivated
MLCK, which led to a reduction in the phosphorylation of MLC.
Furthermore, Boyden chamber experiments showed that tumor
cell migration and invasion were significantly inhibited by
hARD1, and our mutation study revealed that hARD1 associated
with an IgG-C2 motif of MLCK and acetylated the Lys608
residue in this motif. Moreover, K608A-mutated MLCK was not
acetylated or inactivated by hARD1, and its stimulatory effects on
migration and invasion were not inhibited by hARD1. Based on
these results, we propose that hARD1 negatively regulates the
MLCK-mediated migration and invasion of tumor cells (Fig. 7).
ARD1 functions as a catalytic subunit of the N-terminal protein
acetyltransferase complex [20,22,28]. In addition, mouse and
human ARD1s have been reported to participate in post-
translational protein modification via e-amino lysine acetylation,
which is a common means of modifying proteins in eukaryotes. To
date, only two proteins in mammalian cells have been found to be
acetylated by ARD1; in particular, a mouse ARD1 variant (named
mARD1
225) was found to acetylate Lys532 in human HIF-1a [26].
However, since no equivalent of mARD1
225 is expressed in human
cells, it remains unclear whether HIF-1a is regulated by ARD1 in
man [29]. Recently, we have reported that hARD1 directly
acetylates b-catenin and augments b-catenin-dependent cell
proliferation in non-small-cell lung cancer [27]. In the present
study, long MLCK was found to be a novel hARD1-binding
protein and to be acetylated by hARD1. Accordingly, long MLCK
may be a third protein substrate of ARD1 in mammals.
Long MLCK is identical to short MLCK, except that it contains
an N-terminal extension region, which contains six IgG-C2 motifs
and two actin-binding domains. The IgG-C2 motif was originally
identified to be an extracellular domain of adhesion molecules
[30]. To date, this motif has been identified in a number of
intracellular cytoskeletal proteins [31], and found to be involved in
protein-protein interactions [6]. In addition, IgG-C2 motifs in long
MLCK have many putative serine residues that could be
phosphorylated by Ca
2+ signaling [32]. Furthermore, the phos-
phorylations of IgG-C2 motifs activate MLCK, which in turn
Figure 3. hARD1 inhibits the MLCK-dependent MLC phosphor-
ylation. (A) hARD1 negatively regulates the phosphorylation of MLC.
After HT1080 cells were transfected with 80 nM of ARD1 siRNA (si-
ARD1) and/or 2 mg of pcARD1, Western blot analyses were performed.
(B–C) hARD1 inhibits the phosphorylation of MLC MLCK-dependently
but not Rho-kinase-independently. After transfected with 2 mgo f
phARD1 and/or 80 nM of siARD1, HT1080 cells were treated for 16 h
with 20 mM of MLCK inhibitors (ML-7 and ML-9, B) or with 10 mMo fa
Rho-kinase inhibitor (Y27632, C), and then immunoblotted. DMSO was
used as a vehicle control.
doi:10.1371/journal.pone.0007451.g003
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PLoS ONE | www.plosone.org 5 October 2009 | Volume 4 | Issue 10 | e7451Figure 4. hARD1 inhibits migration and invasion of HT1080 cells. (A) Effect of hARD1 on cell migration. HT1080 cells were transfected with
80 nM of siARD1 and/or 2 mg of pcARD1. Cell migration was analyzed for 6 h in transwell chambers with a collagen-coated filter. Cells that had
passed through the filter were stained with haematoxylin and eosin (upper panel). To quantify migrated cells, the stained cells were counted under a
microscope at 406magnification (lower panel). (B) Effect of hARD1 on cell invasion. HT1080 cells were seeded into the upper chamber with a filter
double-coated with Matrigel in the upside and collagen in the downside. After incubated for 16 h, cells that had passed through the filter were
stained (upper panel) and counted (lower panel). (C–D) ARD1 controls cell migration and invasion via MLCK. HT1080 cells were transfected with
pcARD1 or si-ARD1, and then treated with 20 mM of ML-7 or ML-9 for 16 h. Cell migration and invasion were performed as mentioned above. *,
p,0.001 versus the control group (n=6); #, p,0.0001 versus the si-ARD1 group (n=6).
doi:10.1371/journal.pone.0007451.g004
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phosphorylation of Ser19 of MLC has been found to be correlated
with cell motility [33]. In the present study, hARD1 inhibited
MLC phosphorylation by acetylating MLCK, and the hARD1-
binding region on MLCK was found to be located between aa.
497 and 632 in its IgG-C2 region. Furthermore, Lys608 within
  
    
    
                 
      
          
               
Figure 5. Identification of the hARD1-binding domain in long MLCK. (A) In vivo binding of hARD1 to five fragments of MLCK. HEK293 cells
were co-transfected with 4 mg each of pcARD1 and one of pcMyc-MLCK fragments (shown in the upper panel). To examine which region of MLCK is
associated with hARD1, immunoprecipitation was performed with anti-ARD1 antibody and then immunoblotted with anti-Myc antibody (right panel).
The input levels were analyzed by immunoblotting (left panel). An asterisk and an arrow indicate the hARD1-coprecipitated protein band and the
immunoglobulin heavy chain band, respectively. (B) In vivo acetylation of Myc-MLCK_B by hARD1. HT1080 cells were transfected with pcMyc-
MLCK_B (4 mg) and/or si-ARD1 (40 nM or 80 nM). Trichostatin-A (TSA) at 500 nM was treated for 5 h before cell harvest. After immunoprecipitation
with anti-Myc antibody, the lysyl-acetylation of Myc-MLCK_B was identified using anti-acetyl-lysine antibody. (C) In vitro binding of hARD1 to five
fragments of MLCK. The extracted Myc-MLCK peptides were incubated with purified recombinant His-ARD1 at 4uC for 2 h. His-ARD1 was pulled-down
using nickel-affinity beads, and then co-purified Myc-MLCK peptides were identified using anti-Myc antibody. (D) In vitro acetylation of Myc-MLCK
peptides by hARD1. Purified His-ARD1 and Myc-MLCK peptides were incubated in the acetyl-CoA-containing reaction mixture for protein acetylation
at 32uC for 4 h. Acetylated MLCK peptides were identified using anti-acetyl-lysine antibody.
doi:10.1371/journal.pone.0007451.g005
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PLoS ONE | www.plosone.org 7 October 2009 | Volume 4 | Issue 10 | e7451Figure 6. Identification of the acetylation site in long MLCK. (A) In vitro acetylation of MLCK peptides point-mutated at a lysine residue. The
amino acid sequence of expressed MLCK(497–666) peptide is presented in the upper panel. Lysine residue is marked as K in bold font. Wild-type and
mutated peptides were expressed in HEK293 and purified using Flag-affinity chromatography. The peptides and recombinant His-ARD1 protein were
incubated in the reaction mixture for acetylation at 32uC for 4 h, and then lysyl-acetylated peptides were identified using anti-acetyl-lysine antibody
(lower panel). (B) In vivo acetylation of full-length MLCK(K608R) mutant by hARD1. HT1080 cells were co-transfected with 4 mg of pcMLCK or
pcMLCK(K608R) and/or 4 mg of pcARD1, and treated with 1 mM ionomycin, 30 nM PMA, and 0.5 mM TSA for 5 h before cell harvest. After
immunoprecipitation with anti-MLCK antibody, the lysyl-acetylation of MLCK was identified using anti-acetyl-lysine antibody. (C) Lys608 of MLCK is
required for hARD1 to inhibit the MLCK activity on MLC phosphorylation. HT1080 cells were co-transfected with 2 mg of pcMLCK or pcMLCK(K608R)
and/or 2 mg of pcARD1. Cell lysates were immunoblotted by anti-phospho-MLC, anti-MLC, anti-MLCK, and anti-ARD1 antibodies. (D) Lys608 of MLCK
is required for hARD1 to control cell motility. HT1080 cells were co-transfected with 2 mg of pcMLCK or pcMLCK(K608R) and/or 2 mg of pcARD1. Cell
migration (left panel) and invasion (right panel) were analyzed in the transwell system. Migrating cells were stained with haematoxylin and eosin, and
counted at 406magnification. *, p,0.0001 versus the MLCK group (n=6); N.S., not significant statistically (n=6).
doi:10.1371/journal.pone.0007451.g006
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IgG-C2 motif appears to play a critical role in long MLCK
regulation by either phosphorylation or acetylation. In contrast,
other transcripts of the mylk1 gene (short MLCK and telokin) and
skeletal muscle MLCK have no IgG-C2 motif, which encourages
us to speculate that hARD1 only regulates long MLCK but that it
does not control the contractions of skeletal or smooth muscle cells.
hARD1 is expected to regulate cell behavior in association with
the cytoskeletal system.
Ca
2+/calmodulin-dependent activations of MLCK and MLC
stimulate acto-myosin contraction, which promotes cell migration
[34]. According to accepted theory, an increase in cytosolic Ca
2+
concentration causes four calcium ions to bind to calmodulin,
which allows calmodulin to enter the binding pocket at the MLCK
C-terminus, and thereby, activates MLCK [35]. Accordingly, a
high Ca
2+ concentration should be maintained in moving cells,
and in fact, it has been reported that moving cells show a 160–
500% increase in Ca
2+-dependent fluorescence intensity [36].
Thus, under these circumstances, MLCK and MLC are likely to
be constantly activated, which poses the question … How do cells
stop moving? Our findings suggest that hARD1 functions as such a
brake, because hARD1 was found to deactivate MLCK and MLC
specifically in the elevated Ca
2+ state.
In addition to Ca
2+/calmodulin, several protein kinases have
been reported to regulate the enzymatic activity of MLCK. Long
MLCK contains many consensus phosphorylation sites through its
entire region, and the functional consequences of the phosphory-
lations of several of its serine/threonine residues have been well
studied. In particular, the phosphorylation of one of two serine
residues within its calmodulin-binding motif reduces its binding
affinityfor calmodulin, which reduces MLCphosphorylation.Some
protein kinases have been reported to inhibit MLCK-mediated cell
behavior by phosphorylating the sites; these include Ca
2+/
calmodulin-dependent protein kinase II, protein kinase A, protein
kinase C, and p21-activated kinase [6,37]. Furthermore, in addition
to its calmodulin-binding and catalytic domains, two phosphoryla-
tion sites in long MLCK are targeted by members of the MAPK
family, and the phosphorylations of these sites positively regulate
MLCK by increasing its Vmax [11]. In contrast to the known effects
of MLCK phosphorylation, little is known about the effects of
MLCK acetylation. In the present study, we found that hARD1
acetylates Lys608 of long MLCK and negatively regulates MLC
phosphorylation by MLCK. To the best of our knowledge, this is
the first report to claim that MLCK activity is regulated by lysine
acetylation at the post-translational level.
Summarizing, we here identified a novel function of hARD1 in
association with MLCK. Specifically, hARD1 was found to
acetylate and deactivate Ca
2+-activated MLCK, and this was
found to lead to the dephosphorylation of MLC. Furthermore, this
action of hARD1 was found to inhibit tumor cell migration and
invasion. These results suggest that hARD1, a bona fide
endogenous inhibitor of MLCK, can control tumor cell behavior.
Accordingly, we suggest that additional studies be conducted on
MLCK regulation by hARD1, because this study identifies
hARD1 as a novel therapeutic target in the context of preventing
tumor invasion and metastasis.
Materials and Methods
Reagents and antibodies
ML7, ML9, Y27632, ionomycin and BAPTA-AM were
purchased from Calbiochem (La Jolla, CA), and phorbol myristate
acetate (PMA), sodium butyrate (NaBu), and trichostatin-A (TSA)
from Sigma-Aldrich (St Louis, MO). Anti-hARD1 antiserum was
generated in rats against full-length hARD1 peptide [38].
Antibodies against GFP, phospho(Ser439)-MLCK, Myc-epitope,
b-tubulin, and horseradish peroxidase-conjugated secondary
antibodies were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). Anti-acetyl-lysine, anti-MLC and anti-phospho(Ser19)-
MLC were obtained from Cell Signaling Technology (Beverly,
MA), anti-MLCK was from Sigma-Aldrich. Culture media and
fetal calf serum were purchased from Invitrogen (Carlsbad, CA).
Cell culture
HEK293 (human embryonic kidney) and HT1080 (human
fibrosarcoma) cell-lines were obtained from the American Type
Figure 7. A schematic diagram summarizing cell motility regulation by MLCK and hARD1. Long MLCK is activated by the Ca
2+ signaling,
which phosphorylates MLC at Ser19. The phospho-MLC mediates turning of myosin head, which generates the acto-myosin contraction and thus
facilitates cell migration. However, hARD1 acetylates and inactivates MLCK stimulated by the Ca
2+ signaling, which negatively control cell migration.
doi:10.1371/journal.pone.0007451.g007
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Dulbecco’s modified Eagle’s medium, supplemented with 10%
heat-inactivated fetal bovine serum (FBS) in a 5% CO2 humidified
atmosphere at 37uC.
siRNAs and plasmids
The sequences targeting hARD1 (NCBI # NM_003491)
corresponded to nucleotides 311–355 (si-ARD1), 366–392 (si-
ARD1_2), and 528–554 (si-ARD1_3) of the coding region, and
siRNA targeting green fluorescence protein was used as a control.
cDNAs of hARD1 and long MLCK variant 1/2 (NM_053025,
NM_053026) were cloned by reverse transcription and PCR using
Pfu DNA polymerase, and the cDNAs obtained were inserted into
pcDNA vector by blunt-end ligation. The plasmids for Myc-tagged
MLCK fragments and Flag/SBP-tagged MLCK fragments were
constructed by recombining PCR products with the corresponding
plasmids. Point-mutations in MLCK and its fragments were made
by substituting arginine for a lysine in MLCK, using a Quick-
Change
TM site-directed mutagenesis kit (Stratagene, Cedar Creek,
TX).
Immunoblotting and immunoprecipitation
Proteins obtained from cell extracts were separated by SDS/
polyacrylamide gel electrophoresis (PAGE) and then transferred to
Immobilon-P membranes (Millipore; Bedford, MA). Membranes
were blocked with 5% nonfat milk, incubated overnight at 4uC
with primary antibodies diluted 1:1000–2000, and then incubated
for 1 h with horseradish peroxidase-conjugated secondary anti-
bodies. Antigen-antibody complexes were visualized using ECL-
Plus (GE Healthcare, NJ). For immunoprecipitation, cell lysates
were incubated with 5 ml of anti-hARD1 anti-GFP, anti-Myc,
anti-MLCK antiserum, or preimmune serum at 4uC for 2 h.
Immune complexes were further incubated with protein A/G-
Sepharose beads (GE Healthcare) at 4uC for 4 h. Immunocom-
plexes were eluted by boiling for 10 min in a sample buffer
containing 2% SDS and 10 mM dithiothreitol, subjected to SDS/
PAGE and then immunoblotted using anti-hARD1, anti-MLCK,
anti-p-MLCK, or anti-acetyl-lysine antibody.
In vitro binding and acetylation assays
Myc-tagged or Flag/SBP-tagged MLCK peptides were ex-
pressed in HEK293 cells. Flag/SBP-tagged peptides were purified
by Flag-affinity chromatography and eluted with Flag peptide.
His-tagged hARD1 (His-hARD1) was expressed in Escherichia coli
and purified by nickel-beads. For protein binding assays, mixtures
of MLCK peptides (1 mg) and His-hARD1 (0.5 mg) were incubated
at 4uC for 2 h, and protein interactions were identified by nickel-
affinity chromatography and immunoblotting. For acetylation
assays, 0.5 mg of His-hARD1 and 0.5 mg of MLCK peptides were
incubated in a mixture of 50 mM Tris-HCl (pH 8.0), 0.1 mM
EDTA, 1 mM DTT, 10 mM sodium butyrate, 20 mM acetyl-
CoA, and 10% glycerol at 32uC for 4 h. Acetylated MLCK
peptides were identified by immunoblotting with anti-acetyl-lysine
antibody.
Cell migration and invasion assays
For cell migration assays, transwell plates were purchased from
Corning Life Science (Acton, MA). The lower chamber was filled
with culture medium containing 10% FBS as a chemo-attractant.
HT1080 cells (5610
3) in 100 ml of FBS-free medium were seeded
into the upper chamber and incubated at 37uC in a 5% CO2
incubator for 6 h. For invasion assays, 0.5 mg/ml of Matrigel was
loaded on the upper membrane surface. HT1080 cells (2610
4)i n
FBS-free medium were then seeded into the upper chamber and
the lower chamber was filled with FBS-containing medium.
Migrating cells on the lower membrane surface were stained with
hematoxylin and eosin, and counted under an optical microscope
at 40x.
Statistical analyses
All data were analyzed using the unpaired Student t-test in
Microsoft Excel 2003 (Redmond, WA). Results are expressed as
means and standard deviations. Differences between experimental
groups were considered statistically significant at the p,0.05 level.
All statistical tests were 2-sided.
Supporting Information
Figure S1 Cell viability was determined via MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-dipheyltetrazolium bromide] assay. Cells
were plated in 12-well plates and incubated with ML7 (20
microM), ML9 (20 microM), Y27632 (10 microM), Ionomycin (1
microM), PMA (30 nM), BAPTA/AM (20 microM), or DMSO
vehicle in a 5% CO2 incubator for 16 h. After adding the MTT
solution (Sigma-Aldrich) at 0.5 mg/ml, the plates were further
incubated for 3 h. The establishing insoluble formazan was
dissolved with 0.04 N HCl in isopropanol. Cell viability was
determined by the differences in the absorbance at 570 nm using a
spectrophotometer (Molecular devices corporation, CA).
Found at: doi:10.1371/journal.pone.0007451.s001 (0.69 MB TIF)
Figure S2 Immunofluorescence staining of F-actin. After
transfected with pcDNA (2 microg), phARD1 (2 microg), and
siARD1 (80 nM), HT1080 cells were grown on coverslips and
incubated in the presence of 20 microM of ML7, ML9, or DMSO
for 16 h. The cells were washed twice with pre-warmed PBS and
fixed in 3.7% formaldehyde in PBS at room temperature for
10 min. After three times washing with PBS, fixed cells were
blocked with 1% bovine serum albumin in PBS for 30 min and
then stained with Alexa Fluor 633 phalloidin for 10 min.
Fluorescence images were observed using a confocal microscope
(SZ40, Olympus, Japan).
Found at: doi:10.1371/journal.pone.0007451.s002 (1.55 MB TIF)
Figure S3 Purity check of purified recombinant proteins. After
purified through nickel- and Flag-affinity chromatography, His-
tagged hARD1 (1 or 2 microg) and Flag/SBP-tagged MLCK_B (1
or 2 microg) were electrophoresed on SDS/polyacrylamide gels,
and stained with Coomassie Brilliant Blue R-250. Protein band
intensities were quantified using ImageJ 1.36b image analysis
software (NIH, USA), and the protein purity was calculated by
dividing the density of recombinant protein by total densities of
stained proteins.
Found at: doi:10.1371/journal.pone.0007451.s003 (1.60 MB TIF)
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